Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour

Clinical trial NCT01058616 · COMPLETED

Trial details

NCT number: NCT01058616
Sponsor: Lytix Biopharma AS
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Cancer With Transdermal Accessible Tumour

Start date: 2010-01-01
Primary completion: 2013-01-01
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.